Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Jiwon YangJonggi ChoiWon-Mook ChoiKang Mo KimHan Chu LeeJu Hyun ShimPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
The response of metastatic HCC to the Atezo/Bev regimen may be used to determine whether to continue treatment or switch to second-line treatment at an early phase of therapy.